ACC 2019: What the Latest Procedural Advancements Might Mean for Medtech

Posted by Eric Sin on April 16, 2019

Just a couple of weekends ago, I sat in the crowd at the American College of Cardiology (ACC) conference in New Orleans as Dr. Leon and Dr. Reardon presented on transcatheter aortic valve replacement (TAVR) trials in low-surgical-risk aortic stenosis (AS) patients. These findings will not only raise paradigm-shifting questions for the AS market but also prompt discussion around some common industry dilemmas, especially for markets where effective but expensive procedure options become more widely accepted for broader patient populations.


>
Read More

What Medtech Companies Can Learn From Apple's Virtual Clinical Study

Posted by Kate Templeton on March 21, 2019

The American College of Cardiology’s (ACC) Scientific Session and Expo, held March 16-18 in New Orleans, kicked off Saturday morning with the initial results of the much-anticipated Apple Heart Study. For those who keep pace with the fast-moving tech world, I’m sure it felt like an eternity since the study had been announced. But by healthcare standards, the study went quickly and accomplished something unthinkable: It enrolled a breathtaking 419,297 individuals in eight months using a novel, entirely virtual study design.


>
Read More

How COAPT’s ‘All or Nothing’ Trial Design Is Making Sense of a Messy Disease

Posted by Kate Templeton on October 12, 2018

Landmark. Groundbreaking. Blockbuster. All of these words, and then some, have been used to describe Abbott’s recent trial (COAPT) to support MitraClip’s indication expansion to include functional mitral regurgitation.

The trial decisively demonstrated that transcatheter mitral valve repair using MitraClip reduced hospitalizations for heart failure by 47% and all-cause two-year mortality by 38% when compared to medical therapy alone in patients with heart failure and severe functional mitral regurgitation (FMR). When the principal investigator, Dr. Greg Stone, announced the results to a standing-room-only crowd at TCT 2018 last month, the data was met with spontaneous applause.


>
Read More